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Polycythemia vera (PV) is a chronic myeloproliferative disorder whose major morbidity and mortality are thrombohaemorragic
events. Current guidelines advise maintaining hematocrit (HCT) level below 45% in males and 42% in females. Such targets lean
on pathophysiological reasoning, while evidence from ECLAP and PVSG-01, the two largest prospective studies in this disease,
suggests no diﬀerence in the rate of thrombosis in patients maintained at diﬀerent HCT values below 50%–52%. Cytoreductive
therapy in PV (CYTO-PV)is a multicenter, randomized, and controlled trial assess the beneﬁt/risk proﬁle of cytoreductive therapy
with phlebotomy or HU aimed at maintaining HCT < 45% versus maintaining HCT in the range 45%–50%. CYTO-PV is being
conducted in the framework of the Gruppo Italiano Malattie Ematologiche nell’Adulto (GIMEMA) and is funded by the Italian
Drug Agency (AIFA). It is an independent trial with broad recruitment criteria to mimic clinical practice. We describe here the
study and its advancement status. Conclusions. Clinical research in rare disease can be carried out with limited funds, provided a
research hypothesis is felt as clinically relevant by a scientiﬁc community willing to share knowledge on the outcome of clinical
practice, thus producing scientiﬁc results useful to improve treatment and prognosis of patients.
1.Background
Polycythemia vera (PV) is deﬁned as a chronic myelo-
proliferative disorder characterized by clonal proliferation
of hematopoietic progenitors resulting in expansion of the
erythrocyte mass, and its clinical course is aﬀected by
cardiovascular events, the main cause of morbidity and
mortality. Arterial thrombotic events are predominant, par-
ticularly large vessel arterial events including cerebrovascular
accidents, myocardial infarction, and peripheral arterial
occlusion [1, 2].
Considering the lack of eﬀective therapeutic strategy tar-
geted at the mutated allele JAK2V617F, possibly responsible
of the malignancy, current therapies are mainly addressed to
prevent the occurrence of thrombosis.
Based on the complex relationship between thrombosis,
hematocrit, and in vitro parameters of tissue perfusion
and blood viscosity, the latter has been proved to be an
exponential function of the hematocrit. Red cell aggregation
increases at high hematocrit (HCT) levels, creating the
potential for vascular stasis. As a result, enhanced interplay
between platelet, leukocytes and vessel wall increases the risk
of thrombosis [3]. The speciﬁcity of HCT role has been
recently questioned, and the measure of red cell mass has
been suggested to evaluate erytrocytosis in PV in order to
better assess diﬀerences due to contraction or expansion
of plasma volume [4]. However, HCT is the most simple
measure to be used in clinical practice.
An observational, retrospective study suggested that
thrombotic events increase at hematocrit levels higher than2 Thrombosis
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Figure 1: Study design. All patients are to be followed for 5 years with followup visits every 6 months.
44% [5]. Since this old landmark study, HCT level and
its control assumed an essential role in PV. Other small
studies have shown increased incidence of vascular occlusive
events as well as suboptimal cerebral blood ﬂow in ranges of
hematocrit values between 46% and 52% [6]. Accordingly,
the use of an aggressive therapeutic HCT target lower than
45% in males and 42% in females has been recommended
to be adopted to reduce red blood cells and treat PV
patients,preservingthemfromthromboticevents.Currently,
phlebotomyaloneorphlebotomypluscytoreductivedrugsin
patients at high risk of thrombosis are recommended ther-
a p i e st oc o n t r o lH C Tl e v e l s[ 7–11]. So far, no randomized
clinical trial has provided evidence-based data assessing the
usefulness of tight HCT control in reducing thrombosis. The
PVSG-01 and the ECLAP studies, that is, the two largest,
prospective observational studies which are available to date,
were conducted in 431 PV patients followed for a minimum
of 11 years and in 1,638 PV subjects followed for 5 years and
found no clear association between HCT values below 52%
and risk of thrombosis [12, 13].
The American Society of Hematology documented
among hematologists a state of uncertainty about how to
treat PV: 16% to 29% of hematologists surveyed from either
Sweden or the United States used a target hematocrit that
was greater than 45% [14]. Similar practice emerged from
the ECLAP study showing that only 48% of patients were
maintained with hematocrit values below the recommended
target values, whereas 39% and 13% of patients had HCT
values maintained into the 45%–50% range and greater than
50%, respectively.
Notwithstanding the lack of trials providing evidence
as to the best HCT target to be pursed in PV patients,
recommendedtreatmentsincludemaintainingofhematocrit
level below 45% in males and 42% in females through
phlebotomies and/or cytoreductive drugs [15, 16].
CYTO-PV is the ﬁrst large-scale trial testing the eﬃcacy
of diﬀerent intensity of cytoreductive therapy to prevent
thrombotic events in PV patients and has been started in
Italy in the year 2008. This paper presents its status of
advancement and the characteristics of the ﬁrst 319 patients
enrolled into the trial until September, 15 2010.
2.Objective
The study objective is to assess the beneﬁt/risk proﬁle
of cytoreductive therapy, aimed at maintaining hematocrit
(HCT) <45% versus maintaining HCT in the range of 45%–
50%, in patients with PV. The study design is reported in
Figure 1. The population under study will be constituted
by women and men aged +18 years with JAK2 positive
PV diagnosed according to current clinical practice criteria.
Eligible patients will be randomized to maintaining 45% <
HCT < 50% versus HCT < 45%.
3. Patients/Methods
Thisisanindependent,investigator-promotedtrialendorsed
by the Gruppo Italiano Malattie Ematologiche nell’Adulto
(GIMEMA). The CYTO-PV Steering Committee has the
full responsibility for the study design, the collection and
analysis of data, and the interpretation and publication of
study results. The ﬁnancial support has been assured by
a governmental grant from the Italian Agency of Drugs
(AIFA).Thrombosis 3
3.1. Recruitment Criteria. Adults (18+ years) patients with
diagnosis of JAK2 positive PV according with WHO criteria
and written and signed informed consent are being recruited
into the trial.
Exclusion criteria include (a) known hypersensitivity or
contraindication to study treatments, (b) signiﬁcant liver
(AST or ALT > 2.5 times ULN) or renal disease (creatinine
> 2mg/mL), (c) history of active substance or alcohol
abuse within the last year, (d) pregnant or lactating women
or women not protected from pregnancy by an accepted
methodofcontraception,(e)presenceofanylife-threatening
condition or of any disease that is likely to signiﬁcantly
shorten life expectancy, (f) patient refusing to participate
in the study, and (g) any patients’ condition that in the
opinion of the investigator could lead to poor adherence to
the protocol.
The duration of followup is 5 years, and visits will occur
every 6 months. Patients will be treated according to the best
clinical practice.
Nonrandomized patients are included into a prospective
observational register to assess the generalizability of the
CYTO-PV results. Followup visits will be required at the
same intervals as the experimental cohort only for recording
main patients’ characteristics, treatment and the occurrence
of major event such as death, thrombotic or hemorrhagic
events, and diagnoses of leukemia, solid tumors, or myeloﬁ-
brosis. All patients will be administered a questionnaire to
evaluate the quality of life.
The trial aims at assessing if long-term cytoreductive
treatment with phlebotomy and/or hydroxiurea (HU) aim-
ing at the target of HCT < 45% is more eﬀective than
maintaining HCT in the range of 45%–50%. All patients will
be treated with the goal to reach and maintain the target
HCT established with randomization. It is recommended
that patients at high risk of thrombosis (age >65 years or
prior thrombosis) or requiring myelosuppressive therapy for
progressive thrombocytosis or splenomegaly will be given
HU, the myelosuppressive agent of choice. Other treatments,
including radiophosphorus, busulphan, pipobroman, and
alpha-interferon should be considered as second-choice
agents and will be permitted in selected cases according
to the best physician’s judgment. Phlebotomy should be
performed initially by removing 250–500mL of every other
day or twice a week until the target HCT is obtained.
HU should be administered initially at a dose of 0.5–1.0g
daily. The patient is followed with weekly blood counts
adjusting dose to achieve a platelet count <400,000/mmc.
If neutropenia occurs, the dose of HU should be lowered
so as not to reduce leukocyte <3,500/mmc. Blood counts at
regular intervals (monthly) will establish the frequency of
future phlebotomies. Supplemental iron therapy should not
be given.
Because of the open-label design and the type of
experimental treatments, no delivery, labeling, or storage of
drugs is required. Information on study medication will be
collected in the study case report forms (CRF) and kept in
the patient’s source documentation. Compliance to study
treatments will be monitored through the level of HCT
maintained during the trial. It is the speciﬁc investigator’s
responsibility to do her/his best to maintain the hematocrit
in a range compatible with the randomly allocated target by
using pharmacological and/or nonpharmacological “arma-
mentary” currently available. Every eﬀo r tm u s tb em a d et o
ensure that patients remain in the study and are treated for
the entire duration of the study in accordance to the HCT
target allocated by random procedures. If the medication
of a patient is discontinued/changed, the reason(s) for the
discontinuation/change are to be collected and recorded in
the CRF, and the patients must be followed until study
completion with regular followup visits in order to allow
a full evaluation of the study endpoints. A permanent
discontinuation/change of study randomized targets should
be considered only in the best interest of the patients,
but the schedule of followup visits will be followed as
planned by the study protocol. All treatments proven to be
eﬀective for the prevention of cardiovascular disease and
treatment of cardiovascular risk factors which are indicated
for a patient are positively recommended. Administration
of low-dose aspirin is recommended to all patients without
contraindications to the drug.
The ethical conduct of the study is regulated by the last
revision of the Helsinki Declaration as well as the provisions
of the Oviedo Convention. The study protocol is designed to
ensure adherence to good clinical practice (GCP) principles
andprocedures,asdescribedinthefollowingdocumentsand
accepted with their signature by investigators:
(1) ICH Harmonized Tripartite Guidelines for Good
Clinical Practice 1996,
(2) Directive 91/507/EEC, the Rules Governing Medici-
nal Products in the European Community,
(3) US 21 Code of Federal Regulations dealing with
clinical studies (including parts 50 and 56 concerning
informed consent and IRB regulations).
3.2. Eﬃcacy and Safety Evaluation. The primary endpoint
(PEP) is CV death plus thrombotic events (stroke, acute
coronary syndrome (ACS), transient ischemic attack (TIA),
pulmonary embolism (PE), abdominal thrombosis, deep
vein thrombosis (DVT), and peripheral arterial thrombosis).
The secondary endpoint is the assessment of the full
beneﬁt/risk proﬁle of experimental treatments in terms of
eﬃcacy and safety outcome events which include total and
CV hospitalizations, incidence of malignancy, PV-related
malignancy (progression to myeloﬁbrotic, myelodysplastic,
or leukemic transformation), total and nonfatal major
hemorrhage (any hemorrhage requiring transfusion, hospi-
talization, or both), minor bleeding, and any adverse event
leading to permanent discontinuation of treatment (e.g.,
anemia due to phlebotomy).
3.3. Study Organization. Data on baseline characteristics,
laboratorydeterminationandcomorbidityofthepatientsare
collected with the dedicated forms in a web-based, remote
data entry system.4 Thrombosis
Every 6 months until the end of the study, an electronic
followup case report form (e-CRF) will be ﬁlled out pro-
viding data on clinical events, therapy, and adherence to
the study medication. Special forms on death and clinical
outcome events of interest have been created to register all
of the adverse events occurring during the study.
The Steering Committee of the CYTO-PV trial has
delegated the GCP monitoring aspects of the study to
Consorzio Mario Negri Sud. As an investigator-initiated trial
with limited research funds, speciﬁc, centralized monitoring
procedures are activated to assess the reliability of data
collection. Data queries are activated through automated
checksofthedatabaseandvisualinspectionofCRF.Frequent
contacts with the centers will allow to solve all queries timely.
The investigators sent monthly through an automatic e-
mailing system a report on the quality of their work, the
pending issues (e.g., missing CRF, etc.), and the patients they
are expected to visit in the next month. Monitoring visits are
performedtotheresearchsitesaftertheﬁrst2-3patientshave
been enrolled and every 2 years thereafter. Centers with poor
compliancetostudyrequirementsaremonitoredwithadhoc
site visits.
Thearchitectureofthesoftwaredeveloped tomanagethe
clinical trial is based upon the classical 3-tiers model, where:
(1) the client, with an ordinary web browser (running on
a workstation) access,
(2) theapplication(locatedonawebserver),whichinter-
faces with,
(3) a database management system (running on a data-
base server) containing the data storage.
A secure web-based software infrastructure based on
public-key cryptography by using digital certiﬁcates with the
secure sockets layer (SSL) technology has been created to
conduct private, tamper-proof communication with known
parties (coordinating center and recruiting sites).
The key features are (a) administration panel for
managing centers and accounts, (b) remote input/update
and visualization of study case report forms (e-CRFs), (c)
generation of real-time reports (tables) on the progress of
the study (exportable in doc, xls, and pdf formats), (d)
generation of real-time graphs (histograms, lines, and pies)
on the progress of the study, (e) notiﬁcations via e-mail of
actions performed on the website (i.e., user creation, CRF
input/update), (f) automatic sending of periodic reports (in
PDF format) with the summary of the ﬁnalized CRFs and
missing or draft CRFs (with no. of days of delay), and (g) log
all actions taken online by users (tracking log). Each research
site as well as the coordinating center maintain paper copies
of electronic data forms. Real-time computerized validity
and reliability routines have been designed, implemented,
and tested. These routines apply the usual data entry validity
methods: smart prompting, range checking, data consistency
and validity, intelligent ﬁeld/section skipping, as well as spe-
cialized missing data management and automatic summary
score calculation routines with manual overrides. The data
entry programs employ logical consistency checks based
on values from other variables or visit records. Standard
operating procedures deﬁne the query resolution process,
and an audit trail is maintained. SAS is used to generate
additionalreportsregardingcompletenessandconsistencyof
each database.
3.4. Substudies
3.4.1. CY-S1 Substudy. The aim of this substudy is to
evaluate in patients with PV the predictive role of JAK2V617F
allele burden (centrally measured according to real-time
quantitative PCR (RTQ-PCR) on clinical outcomes. The
primaryobjectiveistoascertainthecorrelationoftheburden
of V617F allele, measured at the diagnosis or any time point
thereafter in patients with PV with the clinical characteristics
at the time of blood sampling. Whenever possible, speciﬁc
analyses will be carried out to assess such relationship
at the time of disease diagnosis and of occurrence of
outcome events. The secondary objective is to evaluate time-
dependent change in V617F mutational load in patients
receiving as cytoreductive therapy only phlebotomy versus
HU or other pharmacological therapeutic agents [17, 18].
3.4.2. TG-08 Substudy. This subproject aims to assess the
haemostatic potential through the generation of thrombin
test, as a predictive test on outcome of bleeding and
thrombosis in patients enrolled in CYTO-PV trial. This
substudy will include CYTO-PV patients providing written
and informed consent. By the use of a ﬂuorogenic thrombin
substrate and continuous calibration of each individual
sample, it is possible to obtain a thrombin generation
(TG) curve (or thrombogram) in plasma, with or without
platelets, in an easy routine procedure at high throughput
and with an acceptable experimental error (<5%). The
parameters of the thrombogram, and notably the area under
the curve are useful in assessing bleeding or thrombotic
risk and its modiﬁcation by antithrombotic or haemostatic
treatment [19, 20]. Conditions that increase TG cause
a thrombotic tendency and conditions that decrease TG
prevent thrombosis but, beyond a limit, cause bleeding [21,
22].Thethrombogramcanalsobeusedasatoolinthesearch
for new antithrombotics and reﬂects the haemorrhagic or
thrombotic side eﬀects of other drugs. The thrombogram is
a promising approach to clinical management of bleeding
and thrombotic disease as a tool in drug research and
epidemiology. The project requires the collection of blood
samples at baseline, every 6 months for 5 years and at
the time of occurrence of relevant clinical events (such as
thrombosis or major bleeding).
3.5. Statistical Aspects. The randomization, managed by the
software, is stratiﬁed by center, age (>65 years and ≤65
years), and history of thrombosis using the “biased coin”
algorithm to establish the probability of allocating patients
to the study arms and assure the balance of patients’ charac-
teristics within the randomization strata. The randomization
scheme and data are kept strictly conﬁdential under the
responsibility of the coordinating centre and accessible only
to authorized persons.Thrombosis 5
The minimum followup duration is set at 5 years. Since
in the ECLAP study (median FUP 2.8 years) (9,28), the
cumulative incidence of PEP was 5.5% per year in the overall
population and 6.95% per year in high-risk PV patients,
the expected cumulative rate of the primary endpoint (PEP)
in 5 years of followup is expected to be 5% per year in
the overall of population (25% in 5 years). The minimum
clinically relevant beneﬁcial eﬀect is set at a 30% relative risk
reductionofPEP.1,000patientsareneededtoberandomized
(alpha = 0.05 (two-tailed), beta = 0.2). Similar to an event-
driven trial, the number of expected PEPs which are needed
to allow a reliable evaluation of the eﬃcacy of tested inter-
ventions is set at 130 in the control group for a study power
of approximately 80% at the signiﬁcance level α = 0.05.
Patients will be followed until the occurrence of a suf-
ﬁcient number of PEPs, unless the trial is stopped early
on the basis either of the interim analysis or of new
scientiﬁc evidences. According to the aforementioned, the
study followup will last at least 5 years, provided that:
(i) the rate of events to be observed during the followup
will allow the evaluation of the assumed diﬀerences
between the treatment arms according to the study
design,
(ii) in case the level of signiﬁcance will not be reached at
the interim analysis.
The main analysis will be performed according to an
intention-to-treat approach. Baseline characteristics will be
presented by treatment groups. Any unbalance for baseline
characteristics thought to be of prognostic importance will
be considered for multivariate adjustment in the subsequent
analyses by ﬁtting to the data a Cox proportional hazards
model. The primary analyses of the PEP will be based on the
resulting model. Plots of the Kaplan-Meier estimates of the
survival curves will be presented. Results will be presented
in terms of hazards ratios at their respective 95% conﬁdence
interval. The eﬀect of experimental treatments on mortality,
bleeding, malignancy, and PV-related malignancy will be
assessed in exploratory analysis.
Eﬃc a c yi nt e r m so fP E Pa n do fa l l - c a u s em o r t a l i t y
will be monitored using the sequential procedure of Peto.
One interim analysis to assess eﬃcacy is scheduled at
approximately 1/2 of expected deaths. The corresponding
signiﬁcance level for evidence to stop the trial will be alpha
<0.001. Since PV is a rare disease, the signiﬁcance level of
the ﬁnal analysis will be maintained at P<. 05. No formal
boundaries are proposed for safety, but clear, consistent, and
persistent evidence of net harm that overwhelms any beneﬁt
will be made apparent to the DSMB. A recommendation by
the DSMB to stop the trial will be based on the pattern of
treatment eﬀect across all endpoints, as well as the overall
beneﬁt/risk ratio of tested treatments.
Primary, secondary, and safety outcome measures will be
used for all the subgroup analyses. The eﬀects of the study
treatments will be evaluated in the following predeﬁned
subgroups of patients: pharmacological versus nonpharma-
cological cytoreductive therapy, age (above/below median
value), HCT (≤40%, 40%–45%, 46%–50%, 51%–55%,
>55%), diabetes (y/n), baseline platelet and WBC count
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Figure 2: Enrollment trend during the ﬁrst 2 years. The double line
represent the theoretical enrollment trend. The dotted line shows
the real enrollment trend, and the straight one represents the future
trend to reach the established sample size.
(above/below median value), JAK2 status. In the framework
of multivariate models allowing for possible unbalance for
relevant prognostic covariates, test of interaction will be
carried out ﬁtting a statistical model including each of these
variables, treatment, and their interaction with treatment.
The size of the trial will not allow the evaluation of the
eﬀectsofstudytreatmentonthecombinedprimaryendpoint
with a power higher than 80% in any of the prespeciﬁed
subgroups. Therefore, being in the context of exploratory
analyses,theevaluationofeﬃcacywillbeperformedbyusing
two-sided 90% conﬁdence intervals. Tests of interaction
will be carried out at the 10% signiﬁcance level, too.
Standard statistical methods will be adopted. ANOVA and
t-test will be used for continuous variables. Nonparametric
tests will be adopted for continuous variables in case of
failure of mathematical transformation for normality. Chi-
square and Fisher exact tests will be used for categorical
variables as appropriate. Multivariate analysis using either
logistic regression or Cox proportional hazards models will
be carried out. Time-dependent analysis with time-varying
covariates will be carried out as appropriate.
4. Results
The research network of clinical sites to start the study
needed 8 months to collect the adhesion of the 25 centers
which are currently active in recruiting patients. Forty-one
representatives from 41 divisions of hematology attended
the kick oﬀ meeting the study. Twenty-ﬁve months were
needed to obtain the Institute Review Board approval by
the 29 hospitals which conﬁrmed their participation to the
study and which are to date authorized to recruitment.
The research sites are distributed throughout the national
territory.TheﬁrstpatienthasbeenrandomizedonMay26th,
2008. AsFigure 2shows,319patientshavebeenenrolledinto
the trial until September, 15 2010. In the ﬁrst months of the6 Thrombosis
Table 1: Baseline characteristics.
Patients with of PV Total N = 319
Age at recruitment 64.6 (11.8)
Sex (Males) 198 (62.1)
Years from diagnosis to enrollment 4.4 (5.5)
0–2 146 (45.8)
3–5 69 (21.6)
6–10 64 (20.1)
>10 40 (12.5)
Hematology
Hb g/dL∗ 15.2 (1.7)
HCT %∗ 47.2 (4.6)
Platelets 10(6)/mm3 402 (184)
RBC 10(6)/mm3 5.7 (1.1)
WBC 10(3)/mm3 10.6 (14.9)
Clinical chemistry
Total cholesterol mg/dL 173.1 (41.2)
HDL-cholesterol mg/dL 47.7 (14.2)
LDL-cholesterol mg/dL 99.2 (31.6)
Fasting blood glucose mg/dL 94.1 (22.8)
Prior cardiovascular events
Prior thrombosis 99 (31.2)
Arterial 59 (18.6)
AMI 27 (8.6)
Stroke 10 (3.1)
TIA 14 (4.4)
PAT 2 (0.6)
Extremities 5 (1.6)
Other 2 (0.6)
Venous 43 (13.6)
PE 5 (1.6)
DVT 21 (6.6)
SVT 14 (4.4)
Other 11 (3.5)
Arterial and venous 4 (1.3)
Prior haemorrhagic Events 16 (5.1)
Major bleeding 6 (1.9)
Brain 1 (0.3)
Stroke 0 (0.0)
GI 4 (1.3)
Minor bleeding 10 (3.1)
Erythromelalgia 17 (5.4)
Cardiovascular risk factors and comorbidity
Hypertension 175 (55.2)
Hypercholesterolemia 55 (17.4)
Diabetes mellitus 29 (9.2)
Current smoker 32 (10.1)
Claudicatio intermittent 2 (0.6)
Coronary arterial disease 29 (9.1)
Table 1: Continued.
Patients with of PV Total N = 319
Management of PV disease
Phlebotomy 261 (82.3)
AntiPLT 266 (83.9)
Aspirin 243 (76.7)
Anticoagulant 41 (12.9)
Hydroxyurea 167 (52.7)
32P 0 (0.0)
Busulphan 2 (0.6)
Chorambucil 0 (0.0)
Pipobroman 14 (4.4)
Interferon 7 (2.2)
JAK2 inhibitors 0 (0.0)
Anagrelide 0 (0.0)
Other cytoreductive drugs 3 (1.0)
Treatments for CV risk factors
Hypocholesterolemic medication 43 (13.6)
Anti diabetic medication 16 (5.1)
Anti hypertensive medication 153 (48.3)
Cytogenetics
Jak2 V617F (positive) 307 (96.9)
Jak2 V617F (%) 50.0 (27.6)
Jak2 V617F (negative) 10 (3.2)
Jak2 Exon12 (positive) 5 (1.6)
Jak2 Exon12 (negative) 18 (5.7)
study, the enrollment rate was low because of the few centers
which were authorized to recruit. To date, the recruitment
rate has increased, but is still less than optimal.
Table 1 shows the baseline characteristics of the ﬁrst 319
patients recruited into the trial at 15 September 2010. Main
baseline characteristic are as follows: mean age 65 ± 12
years, females 121 (37.9%). Mean Hct, platelet, red blood,
and white blood cell counts were 47.2%, 402 106/mm3,
5.7 106/mm3, and 10.6 103/mm3, respectively. Ninety-nine
(31.2%) patients had prior thrombosis (59 arterial, 43
venous, 4 both), while only 16 (5.1%) had a prior bleeding.
JAK V617F mutation was present in 307 (96.9%) of patients,
only 5 (1.6%) of patients having the JAK2 exon12 mutation.
Cytoreductive therapy was performed through phlebotomy
as well as prescription of hydroxyurea. In the experimental
arm (Hct 45%–50%) 131 (82.4%) patients have been treated
with phlebotomy, and 84 (52.8%) with HU.
Levels of HCT at baseline are lower than 50% in
approximately 78% of patients (Figure 3).
At 6-month clinical visit in the standard arm (<45%),
130 (82.3%) patients have been treated with phlebotomy
and 83 (52.5%) with HU as cytoreductive therapy and
therapeutic targets were broadly respected in the two arms
for the majority of patients (Table 2), mean HCT values
being 44.4 ± 2.3v e r s u s4 6 .5 ± 2.7. Although the levels of
HCT determined by randomization are broadly maintained,Thrombosis 7
Table 2: Blood cell counts in the two experimental arms of CYTO-
PV at the 6-month after randomization.
HCT < 45%
N = 121
HCT
45–50%
N = 116
P value
HCT % 44.4 (2.3) 46.5 (2.8) <.0001
White blood cells (103/mm3) 9.3 (4.7) 9.3 (4.0) NS
Platelets (103/mm3) 394.4 (169.7) 424.3 (185.0) NS
8.3
15.3
20.4
31.9
24.2
8.9
26.8
15.3
28.7
20.4
0
5
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20
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30
35
<42 42–44.9 45–46.9 47–49.9 ≥50
Hematocrit at baseline
Figure 3: Distribution of HCT values at baseline. The columns
indicate HCT levels before randomization for patients allocated in
the standard (black) and experimental (grey) arms.
Hematocrit (%)
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Figure 4: Distribution of Hematocrit (%) values at baseline and
during6monthFollowupineacharmofCYTO-PVtrial.Theheavy
dotted red line refers to the group of patients allocated to HCT <
45%; the heavy blue line refers to patients in the experimental arm
(HCT 45%–50%).
there is some diﬃculty in maintaining HCT levels lower
than44%.ThoughtheHCTlevelsweresigniﬁcantlydiﬀerent
in the two arms, more than 25% of the subjects in each
arm were not maintained in the therapeutic range allocated
by randomization (Figure 4). At variance with HCT values,
the levels of WBC and platelet count were not signiﬁcantly
diﬀerent between the two treatment arms.
5. Conclusions
The current results of CYTO-PV can be summarized under
two main headings: (1) the trial is feasible, (2) therapeutic
HCT targets allocated with randomization were broadly
respected, but some diﬃculty in maintaining them at the
expected level was found.
The results obtained from the assessment of the ﬁrst 319
patients included in the CYTO-PV trial provide important
information about current management of PV in Italy. In
fact, 244/314 (77.7%) patients had HCT values under the
threshold of 50% before randomization, and 93/314 (29.6%)
already had HCT values below 45%. On the other side, HCT
levels in the two arms at 6 months after randomization
show mean values which are in agreement with the target
allocated randomly, but the standard deviation points out
some diﬃculty in maintaining the level of hematocrit strictly
in the allocated therapeutic range.
In a time of evidence-based medicine, uncertainty as
to the eﬃcacy of controlling PV by maintaining HCT at
speciﬁc levels of HCT in terms of clinically relevant outcome
events cannot be solved through discussion or pathophysio-
logical reasoning. The CYTO-PV study involving 29 Italian
hematological centers represents a simple, but articulated
strategy to investigate on this relevant question, assuring a
reasonable transfer of the best available validated knowledge:
only a multicenter network of clinicians, pathologists, and
epidemiologists can provide the “numbers” of subjects and
give a sound answer to a clinical need of patients aﬀected
by PV; that is, a quasirare disease through the gold standard
of randomized clinical trials (RCTs). The experience of the
ECLAP has shown that the yield of this strategy is not
trivial and is highly cost eﬀective in terms of time and
resources. As it should be clear by now, the trial design
as well as CYTO-PV comes in as the simplest technical
way to deal with uncertainty. Data to be collected, criteria,
contents, intensity of followup, and documentation of the
events are exactly the same as those which are planned and
adopted in routine care. One of the greatest achievements
of the multicenter trials with this orientation has been to
produce a “core” of data and practices, on which the main
analyses will be made, but which at the same time reﬂect
an optimal level of assistance to the majority of patients.
The whole PV patient population as it is “naturally” met
in (or referred to) specialised centres is considered and
suitable for recruitment into a study whose aims are equally
important and which complement each other. CYTO-PV
registry including patients with established criteria could
represent an ideal data-base of the PV population whose
prognostic, diagnostic and assistance proﬁles are compared.
Collected data, criteria, contents, intensity of followup, and
documentation of the events are exactly the same as those
which are planned and adopted in routine care. This leads
to producing a “core” of data and practices, on which the
main analyses will be made, but which at the same time
reﬂect an optimal level of assistance to the majority of
patients.
Finally, the framework of the collaborative studies (reg-
istry and RCT) like CYTO-PV is the ideal setting in which to8 Thrombosis
base more in-depth investigational substudies, with several
important advantages:
(1) a suﬃcient number of patients could be recruited
more rapidly,
(2) it is possible to focus in parallel on various hypothe-
ses, which could complement each other,
(3) patients will be “representative” of the population,
or at least can be traced back to their original
denominators.
The transformation of PV care into a model case for
collaborative research is a diﬃcult objective, from the point
of view of organisation and availability of resources. As is
the case for most clinical conditions which already require
for their care an important investment of personnel and
facilities,theadoptionofaformalresearchprotocolismainly
a “cultural” choice, which has been accepted by the Italian
community of haematologists participating to the trial. Let
us imagine that the concreteness of these variables is not a
hard enough issue so that the trial can be completed and
patients are assured the right to be recruited into a care
strategy, where certainties and uncertainties are given the
speciﬁc methodological and concrete attention they deserve
[23].
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